Danaher Corporation

“Danaher is a structurally exceptional business — deep regulatory moats in bioprocessing, institutionalized operational excellence via DBS, and ~75% recurring revenues producing $5-6B of annual free cash flow through a severe destocking trough. The long-term destination is compelling: bioprocessing, GLP-1 capacity, and diagnostics infrastructure are multi-decade growth vectors with oligopolistic competitive dynamics. However, at $167.88 the stock prices in fair value, not a margin of safety. The base case delivers ~4-5% annualized returns, which does not compensate adequately for the uncertainty around biotech recovery timing, Abcam integration execution, and China localization headwinds. A 15% drawdown toward $140-145 would shift the risk/reward meaningfully and warrant a BUY. Until then, track closely and accumulate only on meaningful weakness.”